Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 3/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23171025 | 0.92 | POLG (0.41) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL23225632 | 0.91 | POLG (0.40) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL25581053 | 0.84 | POLG (0.40) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL19993762 | 0.84 | POLG (0.40) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL19993722 | 0.84 | POLG (0.40) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL22009997 | 0.83 | POLG (0.39) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL18721433 | 0.83 | POLG (0.39) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL19993677 | 0.83 | POLG (0.42) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL20227061 | 0.82 | POLG (0.40) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL25564141 | 0.82 | POLG (0.40) | POLGP2RY2P2RY4P2RY6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3013340-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190054108-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2019-02-21 | — | — | US | disclosed |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190054108-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | POLG 506/4885P2RY2 250/4885P2RY4 129/4885 |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | POLG 1008/4885P2RY2 127/4885P2RY4 58/4885 |
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C3B | POLG 506/4885P2RY2 250/4885P2RY4 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.